Affymax, Inc. (NASDAQ:AFFY) reached a deal with Fresenius (NYSE:FMS) regarding the supply and distribution of Omontys within the organization, influencing Rodman and Renshaw into believing that the deal signifies an important and positive first step for Affymax’s attempts to infiltrate the sizable dialysis organization segment. The firm keeps its Outperform rating and $24 price target on stocks.
McDonald’s Corp. (NYSE:MCD) June U.S. same-store-sales were noticeably above high-end Street expectations, according to Janney Capital’s checks.
Don’t Miss: Is News Corp DUMPING This Property?
Infosys Technologies Ltd. (NASDAQ:INFY) price target was reduced by Wells Fargo to $37-$39 from $45-$46 following the company’s missed Q1 expectations and its reduced FY13 guidance. The firm maintains a Market Perform rating on the shares.
Celgene Corporation (NASDAQ:CELG) announced that a Phase III trial of its drug apremilast for the treatment of psoriatic arthritis met its primary endpoint, causing Rodman and Renshaw to keep labeling the company as its top-pick within the large-cap biotechnology space over the long-term. The firm keeps an Outperform rating and a $76 price target on the stock.
Don’t Miss: Is Google Leaving Apple in its DUST?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.